TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M
Two clinical-stage biotechnology firms, TRex Bio and Retension Pharmaceuticals, hit the public markets on Friday after raising a combined $162 million in their initial public offerings....To view the full article, register now.
Already a subscriber? Click here to view full article